



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Art Unit: 1642
CLASSEN, John B.) Examiner: BRUMBACK, B.
Serial No.: 08/591,651) Washington, D.C.
Filed: February 12, 1996) August 17, 2001
For: METHOD AND COMPOSITION) Docket No.: CLASSEN=1A
FOR AN EARLY VACCINE...)

#39/C
8/23/01
P8

AMENDMENT UNDER RULE 1.115

Honorable Commissioner of Patents
Washington, D.C. 20231

RECEIVED
AUG 21 2001
TECH CENTER 1600/2900

S i r :

In response to the office action mailed February 21, 2001,
please enter the following amendments and remarks:

IN THE CLAIMS

Please cancel claims 69, 70, 75, 76 and 89.

Claims 5, 19, 30, 32, 38, 40, 56, 67, 69-71, 73 and 75-77
have been amended as follows:

5 (amended). The kit of claim 59 wherein one immunogen is provided which is not any of the following immunogens: a BCG, *Hemophilus influenzae*, *Streptococcus pneumoniae*, or *Neisseria* immunogen, or an immunogen of an organism which causes diphtheria, tetanus, pertussis, polio, hepatitis A, hepatitis B, measles, mumps, rubella, influenza, cholera, plague, varicella, rabies, typhoid or yellow fever.

19 (amended). A pharmaceutically acceptable immunogenic agent comprising an immunologically effective amount of at least one pediatric immunogen and of at least one non-pediatric immunogen where said pediatric immunogen is an immunogen of a first human pathogen, and said non-pediatric immunogen is an immunogen of a second and different human pathogen.

30 (amended). The kit of claim 16 wherein said kit contains

G3
08/20/2001 GABRKA1 00000043 08591651

01 FC:203
02 FC:202

03 FC:217

36.00 GP
200.00 GP

465.00 GP